Extract
Asthma and COPD are two common chronic airway diseases associated with high morbidity and mortality [1, 2]. It is estimated that approximately 20% of asthma and COPD have diagnosis or features of both [3]. There is growing appreciation of the need to tease out phenotypes and endotypes across the spectrum of chronic airway diseases [4, 5], to evolve towards precision medicine [6, 7]. While there have been recent large cohort studies following either severe asthma [8] or COPD [9], there is paucity of large real life longitudinal studies investigating both asthma and COPD together with the asthma/COPD overlap across the all disease severity spectrum without any predetermined pharmacological intervention.
Abstract
NOVELTY is a prospective real life observational study that investigates asthma, COPD and asthma/COPD overlap over a period of years with the purpose to relate phenotype and endotype to clinical outcomes and disease trajectories https://bit.ly/3qERZRD
Footnotes
Conflict of interest: R. Louis reports grants and personal fees from GSK, AZ, Chiesi and Novartis, personal fees from Sanofi, outside the submitted work; and has a patent “Method for the diagnosis of airway disease inflammatory phenotype” issued.
Conflict of interest: G. Louis has nothing to disclose.
Conflict of interest: O. Bonhomme has nothing to disclose.
Support statement: This work was supported by the EOS (Excellence of Science) Belgian Federal Program, grant: EOS 30565447. Funding information for this article has been deposited with the Crossref Funder Registry.
- Received March 2, 2021.
- Accepted March 2, 2021.
- Copyright ©The authors 2021. For reproduction rights and permissions contact permissions{at}ersnet.org